Valuation: Alvotech

Market Cap 1.47B 1.28B 1.19B 1.09B 2.06B 140B 2.09B 14.02B 5.5B 69.88B 5.52B 5.4B 234B P/E 2026 *
15.5x
P/E 2027 * 8.99x
Enterprise Value 2.55B 2.22B 2.07B 1.9B 3.58B 244B 3.64B 24.36B 9.56B 121B 9.59B 9.38B 407B EV / Sales 2026 *
3.89x
EV / Sales 2027 * 3.2x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day+15.41%
Current month-56.08%
Current year-56.08%
5 years 3.54
Extreme 3.54
10.44
10 years 3.54
Extreme 3.54
11.62
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
21/09/20 OthersCompany 218,750 3.8889%
16/09/20 OtherCompany 0 0%
16/09/20 OtherCompany 6,468,750 115.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+15.41%+34.64% - - 1.47B
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average +0.19%+1.05%+59.43%+103.27% 27.82B
Weighted average by Cap. -1.50%+2.03%+76.87%+128.10%

Financials

2026 *2027 *
Net sales 656M 571M 531M 488M 921M 62.65B 935M 6.26B 2.46B 31.19B 2.46B 2.41B 105B 793M 689M 641M 589M 1.11B 75.65B 1.13B 7.56B 2.97B 37.66B 2.98B 2.91B 126B
Net income 91.8M 79.8M 74.27M 68.19M 129M 8.76B 131M 876M 344M 4.36B 345M 337M 14.63B 151M 132M 122M 112M 212M 14.45B 216M 1.44B 567M 7.19B 568M 556M 24.12B
Net Debt 1.08B 942M 877M 805M 1.52B 103B 1.54B 10.33B 4.06B 51.49B 4.07B 3.98B 173B 1.07B 926M 862M 791M 1.49B 102B 1.52B 10.16B 3.99B 50.63B 4B 3.91B 170B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
31/07/26 $4.120 +15.41% 1,721,179
30/07/26 $3.570 +1.13% 989,695
29/07/26 $3.530 +13.87% 3,036,187
28/07/26 $3.100 +0.65% 330,587
27/07/26 $3.080 +0.65% 397,899
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
4.120USD
Average target price
5.750USD
Spread / Average Target
+39.56%

Quarterly revenue - Rate of surprise